Using decision tree learning to predict the responsiveness of hepatitis C patients to drug treatment

Yoshihiro Kawamura1, Shigeru Takasaki, Masashi Mizokami

  • 1The Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, 1-7-1 Konodai, Ichikawa, Chiba 272-8516, Japan.

FEBS Open Bio
|May 8, 2013
PubMed

Insights

Predicting hepatitis C virus (HCV) genotype 1 treatment success is crucial. A new decision tree model using genetic data accurately predicts patient response to pegylated interferon-α and ribavirin therapy.

Area of Science:

  • Hepatology
  • Genetics
  • Bioinformatics

Background:

  • Standard hepatitis C treatment (pegylated interferon-α plus ribavirin) has limited efficacy for genotype 1.
  • Predicting treatment outcomes is essential for personalized medicine in chronic hepatitis C.

Purpose of the Study:

  • To develop a predictive model for sustained virologic response in hepatitis C virus genotype 1 patients.
  • To utilize genome-wide association study data and decision tree learning for treatment outcome prediction.

Main Methods:

  • A decision tree learning model was applied to genetic data (SNPs) from 142 Japanese patients with HCV genotype 1.
  • Patient data included those with null virologic response (78) and virologic response (64).

Main Results:

  • The decision tree model achieved a high prediction accuracy of 93% for treatment response.
  • The model effectively distinguishes patients likely to benefit from standard therapy.

Conclusions:

  • A novel, accurate prediction method for HCV genotype 1 treatment response has been developed.
  • This approach, using genetic markers and machine learning, can guide clinical decisions for hepatitis C patients.

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Survival Tree01:19

Survival Tree

Survival trees are a non-parametric method used in survival analysis to model the relationship between a set of covariates and the time until an event of interest occurs, often referred to as the "time-to-event" or "survival time." This method is particularly useful when dealing with censored data, where the event has not occurred for some individuals by the end of the study period, or when the exact time of the event is unknown.
 Building a Survival Tree
Constructing a survival tree begins...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...